Stockscreener 앱 받기
0.629
4.82%
0.0289
시간 외 거래:
.60
-0.029
-4.61%
전일 마감가:
$0.6001
열려 있는:
$0.62
하루 거래량:
333.64K
Relative Volume:
1.13
시가총액:
$43.38M
수익:
$2.98M
순이익/손실:
$-15.29M
주가수익비율:
-2.4638
EPS:
-0.2553
순현금흐름:
$-14.25M
1주 성능:
-8.70%
1개월 성능:
+8.52%
6개월 성능:
-40.10%
1년 성능:
-57.50%
1일 변동 폭
$0.6046
$0.6339
1주일 범위
$0.58
$0.7368
52주 변동 폭
$0.5401
$1.40
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.629 | 41.38M | 2.98M | -15.29M | -14.25M | -0.2553 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2025 Earnings Call Transcript - Insider Monkey
IceCure reports net loss of USD 15,057,000 in 2025 - Medical Buyer
Icecure Medical Rides FDA, ASBRS Wins to Growth - TipRanks
IceCure Medical Discloses Resignation of Director Li Haixiang - TipRanks
IceCure Medical (ICCM) director Li Haixiang steps down from board - Stock Titan
IceCure Medical (ICCM) Q4 2025 Earnings Transcript - AOL.com
IceCure Medical 2025 Financial Results Review | ProSense System UpdatesNews and Statistics - IndexBox
IceCure Medical (ICCM) Fourth Quarter 2025 Earnings Call Transcript - Bitget
IceCure Medical Ltd Q4 2025 Earnings Call Summary - Yahoo Finance
ICCM: Record revenue and regulatory milestones drive rapid adoption and expansion for ProSense - TradingView
ICCM: Record revenue and regulatory milestones fuel rapid adoption and growth outlook for ProSense - TradingView
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ICCM Reports Record FY25 Revenue Growth Following Key FDA Cleara - GuruFocus
IceCure Medical Posts Record 2025 Sales as ProSense Cryoablation Adoption Accelerates Post-FDA Clearance - TipRanks
Icecure Medical Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
IceCure Medical (NASDAQ: ICCM) 20-F details going concern risk and FDA breast cancer OK - Stock Titan
IceCure Reports 2025 Full Year Financial & Operational Results - PR Newswire
Hedge Fund Bets: Is IceCure Medical Ltd forming a breakout pattern2026 Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
IceCure (ICCM) updates auditor consent in Form F-3/A shelf amendment - Stock Titan
What To Expect From Icecure Medical Ltd (ICCM) Q4 2025 Earnings - GuruFocus
IceCure Medical : Company Presentation - marketscreener.com
New Highs: Is IceCure Medical Ltd subject to activist investor interest2026 Trade Ideas & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Icecure Medical Ltd expected to post a loss of 4 cents a shareEarnings Preview - TradingView
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer - Finviz
FDA Greenlights IceCure’s ProSense® Study for Breast Cancer - Zenopa
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for Pr - GuruFocus
IceCure Wins FDA Nod for U.S. Post-Marketing ChoICE Study of ProSense Cryoablation in Low-Risk Breast Cancer - TipRanks
FDA clears IceCure (Nasdaq: ICCM) ProSense post-market ChoICE study in breast cancer - Stock Titan
IceCure Medical (ICCM) Receives FDA Approval for Post-Market Stu - GuruFocus
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer - PR Newswire
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 - The Malaysian Reserve
Movement Recap: Is IceCure Medical Ltd showing insider buyingRecession Risk & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Tumor-freezing firm IceCure to detail 2025 results on Mar. 17 - Stock Titan
American Society of Breast Surgeons (ASBrS) Resource Guide Updat - GuruFocus
IceCure Gains Key ASBrS Backing for ProSense Cryoablation in Low-Risk Breast Cancer - TipRanks
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer - PR Newswire
Meme Stocks: Can IceCure Medical Ltd outperform under higher oil pricesTrade Performance Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Bank Watch: Is IceCure Medical Ltd a strong candidate for buy and holdJuly 2025 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Sell Signal: Is IceCure Medical Ltd a stock for growth or value investors2025 Market WrapUp & AI Powered Market Trend Analysis - baoquankhu1.vn
Does IceCure Medical Ltd outperform in volatile markets2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
IceCure Medical Highlights New PLOS One Data Showing ProSense Cryoablation Effective for Breast Fibroadenomas - TipRanks
Independent ProSense study on breast tumors for IceCure (ICCM) - Stock Titan
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas - Barchart.com
ICCM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ICCM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ICCM Should I Buy - Intellectia AI
ICCM Completes Key 5-Year Follow-Up in Kidney Cancer Clinical Tr - GuruFocus
IceCure Medical Completes Five-Year Follow Up in ICESECRET Kidney Cancer Cryoablation Study - TipRanks
S P Trends: Is IceCure Medical Ltd subject to activist investor interest2025 Volatility Report & Risk Managed Trade Strategies - baoquankhu1.vn
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 - PR Newswire
A freezing treatment for kidney tumors just finished 5 years of testing - Stock Titan
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):